The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer

Lung cancer (LC) is the deadliest malignancy worldwide. In an operable stage I–III patient setting, the detection of minimal residual disease (MRD) after curative treatment could identify patients at higher risk of relapse. In this context, the study of circulating tumor DNA (ctDNA) is emerging as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Verlicchi, Alberto, Canale, Matteo, Chiadini, Elisa, Cravero, Paola, Urbini, Milena, Andrikou, Kalliopi, Pasini, Luigi, Flospergher, Michele, Burgio, Marco Angelo, Crinò, Lucio, Ulivi, Paola, Delmonte, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532754/
https://www.ncbi.nlm.nih.gov/pubmed/37763318
http://dx.doi.org/10.3390/life13091915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532754/
https://www.ncbi.nlm.nih.gov/pubmed/37763318
http://dx.doi.org/10.3390/life13091915

Ejemplares similares